Cavendish maintains buy on hVIVO after influenza trial contract win, sees revenues weighted to 2026

Cavendish has maintained its 'buy' recommendation and 16.5p target price on hVIVO PLC (AIM:HVO) following the clinical development specialist's announcement of a new influenza human challenge trial contract with Traws Pharma. The broker described the deal as consistent with the company's strong offering in the antiviral market.